

Trevena is a clinical stage biopharmaceutical company discovering and developing G-protein coupled receptors (GPCR) biased ligands. Among its major competitors, Trevena is ranked in 8th place for NPS while Biogen is 1st, and Athersys is 2nd.Their current market cap is $11.41M